Michele Yeung1, Kaylee Ho2, Monica N Fornier3,4, Azeez Farooki5. 1. Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 2. Division of Biostatistics, Weill Cornell Medical College, New York, NY, USA. 3. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 5. Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
Background: Denosumab is approved to prevent fragility fractures in patients with osteoporosis at high risk for fracture and to prevent bone loss in patients with breast and prostate cancer who receive endocrine therapy. The antiresorptive effect of denosumab rapidly dissipates when it is delayed or discontinued, but the risk for, and incidence of, multiple clinical vertebral fractures in patients with breast cancer after stopping denosumab is currently unclear. Question/Purposes: We sought to identify the incidence of clinical vertebral fractures in patients with breast cancer who received at least 2 doses of denosumab (60 mg) and then discontinued the medication. Methods: We conducted a retrospective chart review to identify patients with a history of breast cancer who were treated with denosumab between June 1, 2010, and July 18, 2018, at Memorial Sloan Kettering Cancer Center. We identified 335 postmenopausal women and 1 man with nonmetastatic breast cancer who received their final denosumab injection at least 6.5 months earlier. Data recorded included baseline bone density and the incidence of vertebral fractures after denosumab discontinuation. Results: The median age of patients was 62 years. Patients received between 2 and 13 denosumab doses before drug discontinuation. Most of the patients (310; 92.3%) were also treated with aromatase inhibitors. Of the 194 patients with baseline bone density data, 50 (25.8%) had normal bone density, 97 (50.0%) had osteopenia, and 47 (24.2%) had osteoporosis. The median follow-up duration from the last denosumab dose was 18.5 months. We identified 1 case of spontaneous vertebral fractures after denosumab stoppage. We found no cases of osteonecrosis of the jaw or atypical femur fracture. Most of the patients (88%) had a gap in denosumab dosing. Conclusions: Clinicians treating patients with breast cancer-especially those continuing to take aromatase inhibitors-should be aware of the possible risks of delaying doses of or discontinuing denosumab and should educate their patients accordingly. Prospective studies are needed to fully evaluate the risks of stopping or delaying denosumab.
Background: Denosumab is approved to prevent fragility fractures in patients with osteoporosis at high risk for fracture and to prevent bone loss in patients with breast and prostate cancer who receive endocrine therapy. The antiresorptive effect of denosumab rapidly dissipates when it is delayed or discontinued, but the risk for, and incidence of, multiple clinical vertebral fractures in patients with breast cancer after stopping denosumab is currently unclear. Question/Purposes: We sought to identify the incidence of clinical vertebral fractures in patients with breast cancer who received at least 2 doses of denosumab (60 mg) and then discontinued the medication. Methods: We conducted a retrospective chart review to identify patients with a history of breast cancer who were treated with denosumab between June 1, 2010, and July 18, 2018, at Memorial Sloan Kettering Cancer Center. We identified 335 postmenopausal women and 1 man with nonmetastatic breast cancer who received their final denosumab injection at least 6.5 months earlier. Data recorded included baseline bone density and the incidence of vertebral fractures after denosumab discontinuation. Results: The median age of patients was 62 years. Patients received between 2 and 13 denosumab doses before drug discontinuation. Most of the patients (310; 92.3%) were also treated with aromatase inhibitors. Of the 194 patients with baseline bone density data, 50 (25.8%) had normal bone density, 97 (50.0%) had osteopenia, and 47 (24.2%) had osteoporosis. The median follow-up duration from the last denosumab dose was 18.5 months. We identified 1 case of spontaneous vertebral fractures after denosumab stoppage. We found no cases of osteonecrosis of the jaw or atypical femur fracture. Most of the patients (88%) had a gap in denosumab dosing. Conclusions: Clinicians treating patients with breast cancer-especially those continuing to take aromatase inhibitors-should be aware of the possible risks of delaying doses of or discontinuing denosumab and should educate their patients accordingly. Prospective studies are needed to fully evaluate the risks of stopping or delaying denosumab.
Authors: Michael Gnant; Georg Pfeiler; Peter C Dubsky; Michael Hubalek; Richard Greil; Raimund Jakesz; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger; Vesna Bjelic-Radisic; Silvia Artner-Matuschek; Florian Fitzal; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Günther G Steger; Diether Manfreda; Ruth Exner; Daniel Egle; Jonas Bergh; Franz Kainberger; Susan Talbot; Douglas Warner; Christian Fesl; Christian F Singer Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Elena Tsourdi; Bente Langdahl; Martine Cohen-Solal; Bérengere Aubry-Rozier; Erik Fink Eriksen; Nuria Guañabens; Barbara Obermayer-Pietsch; Stuart H Ralston; Richard Eastell; M Carola Zillikens Journal: Bone Date: 2017-08-05 Impact factor: 4.398
Authors: O Lamy; E Fernández-Fernández; I Monjo-Henry; D Stoll; B Aubry-Rozier; D Benavent-Núñez; P Aguado; E Gonzalez-Rodriguez Journal: Osteoporos Int Date: 2019-01-06 Impact factor: 4.507
Authors: Athanasios D Anastasilakis; Socrates E Papapoulos; Stergios A Polyzos; Natasha M Appelman-Dijkstra; Polyzois Makras Journal: J Bone Miner Res Date: 2019-10-14 Impact factor: 6.741
Authors: Steven R Cummings; Serge Ferrari; Richard Eastell; Nigel Gilchrist; Jens-Erik Beck Jensen; Michael McClung; Christian Roux; Ove Törring; Ivo Valter; Andrea T Wang; Jacques P Brown Journal: J Bone Miner Res Date: 2017-11-22 Impact factor: 6.741
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316